Evidence map›Paper›PMID 42743209›Full record

ArticlePloS one2026

Estimating cumulative incidence from partially missing time series of respiratory viral infections.

Sudhir Venkatesan, Lisa White, Hyewon Nina Koo, John Dickerson, Weiming Hu, Jennifer Kuntz, Mark Schmidt, Sylvia Taylor, Carla Talarico

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sudhir VenkatesanBPM Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.ORCID https://orcid.org/0000-0002-2093-5781
Lisa WhiteModel Health Ltd, Brixham, United Kingdom.ORCID https://orcid.org/0000-0002-6523-185X
Hyewon Nina KooData Science and Artificial Intelligence, BioPharmaceuticals R&D, AstraZeneca, Mölndal, Sweden.
John DickersonKaiser Permanente Center for Health Research, Portland, Oregon, United States of America.
Weiming HuKaiser Permanente Center for Health Research, Portland, Oregon, United States of America.
Jennifer KuntzKaiser Permanente Center for Health Research, Portland, Oregon, United States of America.
Mark SchmidtKaiser Permanente Center for Health Research, Portland, Oregon, United States of America.
Sylvia TaylorMedical Evidence, Vaccines and Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom.
Carla TalaricoMedical Evidence, Vaccines and Immune Therapies, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSeasonal respiratory viruses, including respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), are major contributors to global respiratory infection burden. Estimating viral incidence using real-world data (RWD) is challenging as misalignment of data collection with seasonal circulation can lead to underestimated incidence and hinder inter-study comparisons.

methodsWe developed a regression-based approach to retrospectively correct partial-season time series with contiguous missing weeks at the start or end of a season. Weekly RSV clinical incidence (per 100,000) was extracted from U.S. RWD sources (Optum® CDM and PharMetrics Plus, adults ≥65 years; Kaiser Permanente Northwest [KPNW], all ages) for seasons 2018-19 to 2023-24 and aligned to RSV‑Net hospitalization surveillance. Weekly early- and late-season missingness scenarios were created (approximately 10%, 15%, 20%, and 25% of weeks removed). Models were fit within each season using harmonic terms and the surveillance-aligned covariate. Uncertainty was quantified using moving block bootstrap 95% prediction intervals. Weekly accuracy was evaluated using RMSE and normalized RMSE, and seasonal burden reconstruction accuracy using cumulative percent error and signed difference. For hMPV, we evaluated an illustrative extension using Optum® CDM (adults ≥65 years; 2022-23 and 2023-24) and NREVSS test positivity; because positivity is bounded and depends on testing volume, we used a denominator-aware binomial/logit model (positives out of tests).

resultsFor RSV, weekly prediction error increased with missingness level, while reconstructed seasonal burden generally remained close to observed totals in applicable scenarios. Early-season gaps were associated with larger cumulative errors than late-season gaps in Optum® CDM and PharMetrics Plus, whereas late-season median percent errors were closer to zero across missingness levels. Applicability was reduced primarily for higher early-season missingness in KPNW due to peak overlap (e.g., early 25% scenarios not applicable). For hMPV test positivity (illustrative; two seasons), weekly prediction RMSE was on the order of ~1-2 percentage points across missingness scenarios.

conclusionAcross multiple RSV seasons and data sources, reconstructed seasonal burden generally agreed with observed totals when missingness was confined to contiguous early- or late-season weeks and did not overlap peak activity. This approach provides a transparent method to improve the utility and comparability of partial-season respiratory virus time series. However, applicability is reduced when peak weeks are missing, and hMPV findings are illustrative given limited seasons and the use of test positivity.

Indexed as

Paramyxoviridae InfectionsRespiratory Syncytial Virus InfectionsRespiratory Tract InfectionsHumansIncidenceMetapneumovirusRespiratory Syncytial Virus, HumanRetrospective StudiesSeasonsUnited States

Identifiers

PMID42743209
PMCPMC13577586

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.